Abstract: The invention comprises antigenic glycoproteins substantially similar to antigenic glycoproteins present on the surface of the merozoite form of Plasmodium falciparum, including glycoproteins of molecular weights of about 56,000 present in the Geneva and FVO isolates and about 50,000 that is present in the Honduras I/CDC, Indochina 1, Kenya and Tanzania I isolates. The invention also comprises monoclonal antibodies 4-8-5D (HB 8938) which bind to the 56,000 glycoprotein of the invention, a hybridoma cell line that is capable of producing these monoclonal antibodies, and vaccines and vaccine compositions comprising these glycoproteins or epitopes substantially similar to or cross reactive with these glycoproteins or genes or gene fragments encoding such epitopes.
Abstract: Adenine deaminase-stable adenine derivatives bonded 9,1' to a furanosidyl ring containing a 5'-hydroxyl group are described. These compounds are useful in a method of inhibiting replication of reverse transcriptase-dependent viruses.
Abstract: New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.
Type:
Grant
Filed:
April 6, 1987
Date of Patent:
December 25, 1990
Assignees:
Scripps Clinic and Research Foundation, Rorer Biotechnology Inc.
Inventors:
Dorothea H. Scandella, William N. Drohan, Theodore S. Zimmerman, Carol A. Fulcher
Abstract: A synthetic polypeptide is disclosed that substantially corresponds in sequence to a portion of the amino acid residue sequence of the 90 amino acid residue extra type III domain of human cellular fibronectin from about position 36 to about position 60 from the amino-terminus. The polypeptide contains about 10 to about 25 amino acid residues. Also disclosed are antibodies and methods of using both the polypeptide and antibodies.
Type:
Grant
Filed:
April 15, 1986
Date of Patent:
December 25, 1990
Assignee:
Scripps Clinic and Research Foundation
Inventors:
John H. Peters, Mark H. Ginsberg, Charles G. Cochrane
Abstract: DNA sequences are described which encode Plasmodium falciparum merozoite antigenic surface proteins and protein fragments. Corresponding recombinant plasmids and transformed bacterial strains are described. The proteins and fragments have utility for immunological and diagnostic purposes.
Type:
Grant
Filed:
June 1, 1989
Date of Patent:
December 18, 1990
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Feroza Ardeshir, Janette E. Flint, Robert T. Reese
Abstract: Recombinant 540 amino acid residue and 517 amino acid residue proteins encoded by the genome of Mycobacterium tuberculosis are disclosed as are vectors for propagating their DNA sequences and expressing the proteins. Also disclosed are methods for using those proteins. Peptides that correspond substantially to the sequences of those proteins and methods of their use are also disclosed, as are polymers containing peptide repeating units corresponding to the 540 residue protein and also polymers containing 517 protein pentapeptides as repeating units.
Abstract: Novel hybridoma cell lines producing monoclonal antibodies which react specifically with human pancreatic cancer cells are described. Methods for producing antigenic preparations to generate the hybridoma cell lines and for selecting, purifying and characterizing the monoclonal antibodies reactive with human cells, including pancreatic cancer cells, are disclosed.
Abstract: A compound comprising a deletion analogue of an amide or carboxy-terminating Magainin I of the following structural formula using the single letter amino acid code: ##STR1## and wherein at least one of amino acid residues 15 through 23 is omitted; or a deletion analogue of an amide or carboxy-terminated Magainin II of the following structural formula using the single letter amino acid code: ##STR2## and wherein at least one of amino acid residues 15 through 23 is omitted. These compounds can be effectively used as pharmaceutical compositions.
Abstract: The present invention relates to systems and methods used to assay for particular complement component fragments. The invention can be used to determine the amount of a particular complement component fragment in a sample. The fragment can be fluid phase or bound to an immune complex. Generally, specific binding agents, such as antibodies, directed to the complement component fragments and immune complexes are used in the assay.
Type:
Grant
Filed:
June 30, 1988
Date of Patent:
October 2, 1990
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Argyrios N. Theofilopoulos, Frank J. Dixon, Maria-Teresa Aguado-Celada
Abstract: Recombinant 540 amino acid residue and 517 amino acid residue proteins encoded by the genome of Mycobacterium tuberculosis are disclosed as are vectors for propagating their DNA sequences and expressing the proteins. Also disclosed are methods for using those proteins. Peptides that correspond substantially to the sequences of those proteins and methods of their use are also disclosed, as are polymers containing 517 protein pentapeptides as repeating units.
Abstract: Compositions and methods for their use in modulating animal cellular responses are disclosed. The compositions include as an active agent an effective amount of an 8-substituted guanine derivative bonded 9-1' to an aldose having 5 or 6 carbon atoms in the aldose chain. The composition includes a diluent amount of a physiologically tolerable carrier. The guanine derivative is free of electrically charged funtionality, while the 8-substituent has an electron withdrawing inductive effector greater than that of hydrogen and contains fewer than about 15 atoms. Anmimal cellular responses are modulated by contacting the cells with a composition of this invention.
Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, polypeptides related to HBxAg and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.
Abstract: The present invention contemplates a method of preventing platelet dependent arterial thrombosis using a halogen-methyl ketone-containing peptide represented by Formula (1) as shown in FIG. 1, or a hydrohalic addition product thereof. More particularly, the present invention provides improved methods for inhibiting arterial restenosis, hemodialysis and the like.
Abstract: Synthetic polypeptides whose sequences correspond substantially to amino acid residue sequences of at least portions of naturally occurring proteinoids translated from brain-specific mRNAs are disclosed as are receptors, methods and diagnostics that utilize those synthetic polypeptides. The synthetic polypeptides have molecular weights less than those of their corresponding proteinoids, and induce the production of antibodies that bind to the naturally occurring proteinoid, or a derivative thereof when bound to a carrier as a conjugate and are introduced into an animal.
Abstract: A phosphorous-containing analog-ligand having a conformation that substantially corresponds to the conformation of an amide- or ester-forming transition state is used to induce production of receptor molecules whose antibody combining sites have amide or ester synthase catalytic activity when reacted with a ligand containing (i) a carbonyl carbon atom and (ii) an amine or alcohol group that are structurally capable of forming a preselected carboxylic amide or ester bond.
Type:
Grant
Filed:
May 28, 1987
Date of Patent:
February 13, 1990
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Stephen Benkovic, Richard A. Lerner, Alfonso Tramontano, Andrew D. Napper
Abstract: Animal cellular responses, and particularly immune-related responses, are modulated by contacting such cells with a unit dose of a composition containing an effective amount of an isoxanthopterin-8-aldoglycoside. An isoxanthopterin has a structure that conforms to the formula ##STR1## wherein R.sub.1 is a substituent and R.sub.2 is an aldoglycoside.
Abstract: Antigens, immunogens, inocula, antibodies, receptors, diagnostic methods and systems relating to tuberculosis mycobacteria are disclosed. Each of the compounds, compositions, methods or systems contains about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the thirteen or fourteen amino acid reside sequence (AlaLysValAsnIleLysProLeuGluAspLysIleCys) or (CysAlaLysValAsnIleLysproLeuGluAspLysIleCys). When linked to a carrier and introduced in an effective amount into a mammalian host, the polypeptide is capable of inducing production of antibodies that immunoreact with an antigen to a tuberculous mycobacterium.
Type:
Grant
Filed:
August 21, 1987
Date of Patent:
December 26, 1989
Assignee:
Scripps Clinic and Research Foundation
Inventors:
Thomas M. Shinnick, Percy Minden, Richard A. Houghten
Abstract: A synthetic polypeptide having at least about 10% of the immunological activity of biologic heat-stable enterotoxin of E. coli. The synthetic polypeptide includes at least 14 amino acids in the sequence, from amino-terminus to carboxy-terminus, represented by the formula: CysCysGluLeuCysCysTyr-(Asn)ProAlaCysAla(Thr)GlyCysAsn(Tyr) wherein the amino acid in parentheses may replace the immediately preceding amino acid residue, and at least one intramolecular disulfide bond formed between the Cys residues. The Cys residues that are not part of the intramolecular disulfide bond can be replaced by other amino acid residues or be bonded to substituent moieties. The polypeptides can be a monomeric or multimeric material containing an intramolecular, intrapolypeptide and/or an intramolecular, interpolypeptide cystine disulfide bond.
Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.
Type:
Grant
Filed:
October 7, 1987
Date of Patent:
November 21, 1989
Assignee:
Scripps Clinic and Research Foundation
Inventors:
George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan